WAVE LIFE SCIENCES LTD (WVE)
SG9999014716 - Common Stock
Taking everything into account, WVE scores 3 out of 10 in our fundamental rating. WVE was compared to 198 industry peers in the Pharmaceuticals industry. The financial health of WVE is average, but there are quite some concerns on its profitability. WVE is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year WVE has reported negative net income.
WVE had a negative operating cash flow in the past year.
In the past 5 years WVE always reported negative net income.
WVE had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -20.92%, WVE is in the better half of the industry, outperforming 61.22% of the companies in the same industry.
WVE has a Return On Equity of -121.08%. This is in the lower half of the industry: WVE underperforms 63.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.92% | ||
| ROE | -121.08% | ||
| ROIC | N/A |
ROA(3y)-63.5%
ROA(5y)-62.46%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for WVE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
WVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
WVE has more shares outstanding than it did 1 year ago.
WVE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -3.86, we must say that WVE is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.86, WVE is not doing good in the industry: 60.71% of the companies in the same industry are doing better.
There is no outstanding debt for WVE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.86 |
ROIC/WACCN/A
WACC9.23%
2.3 Liquidity
WVE has a Current Ratio of 1.26. This is a normal value and indicates that WVE is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.26, WVE is doing worse than 81.63% of the companies in the same industry.
WVE has a Quick Ratio of 1.26. This is a normal value and indicates that WVE is financially healthy and should not expect problems in meeting its short term obligations.
WVE has a Quick ratio of 1.26. This is in the lower half of the industry: WVE underperforms 73.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.26 |
3. Growth
3.1 Past
WVE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.18%, which is quite impressive.
Looking at the last year, WVE shows a very strong growth in Revenue. The Revenue has grown by 2995.79%.
The Revenue has been growing by 51.05% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)74.18%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q68.09%
Revenue 1Y (TTM)2995.79%
Revenue growth 3Y78.03%
Revenue growth 5Y51.05%
Revenue growth Q2Q2243.23%
3.2 Future
The Earnings Per Share is expected to grow by 10.55% on average over the next years. This is quite good.
Based on estimates for the next years, WVE will show a quite strong growth in Revenue. The Revenue will grow by 9.17% on average per year.
EPS Next Y-85.47%
EPS Next 2Y-40.04%
EPS Next 3Y-16.9%
EPS Next 5Y10.55%
Revenue Next Year-26.58%
Revenue Next 2Y-28.74%
Revenue Next 3Y-5.64%
Revenue Next 5Y9.17%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
WVE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year WVE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
WVE's earnings are expected to decrease with -16.90% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-40.04%
EPS Next 3Y-16.9%
5. Dividend
5.1 Amount
No dividends for WVE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
WAVE LIFE SCIENCES LTD
NASDAQ:WVE (4/19/2024, 12:38:38 PM)
4.815
+0.02 (+0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap588.78M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.92% | ||
| ROE | -121.08% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)74.18%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-85.47%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)2995.79%
Revenue growth 3Y78.03%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y